ArticleScientific reports2025
Preoperative arterial and venous CT radiomics for survival prediction after pylorus preserving pancreatoduodenectomy in pancreatic head cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
- Predicting overall survival in pancreatic ductal adenocarcinoma usingEJNMMI research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PaCa) is the seventh leading cause of cancer deaths globally, with limited detection and treatment. Pancreatoduodenectomy (PD) is the primary surgical intervention for resectable pancreatic head cancers (PaHCa), but its complexity necessitates prognostic tools. This study evaluates the arterial and venous phase radiomic features role from preoperative CT scans in predicting survival for PaHCa patients undergoing pylorus-preserving pancreatoduodenectomy (PPPD). A retrospective analysis was conducted on 42 PaHCa patients (mean age 63.3 ± 10 years; 20 males, 22 females) who underwent PPPD between 2010 and 2017. Radiomic features were extracted from arterial and venous phase CT images, and a gradient boosting survival model was applied for survival prediction using cross-validation. Ethical approval (Approval number: EK028/19, date: 03.05.2019) was granted, and informed consent was waived due to the retrospective nature of the study and all experiments were performed in accordance with relevant guidelines and regulations. No identifying information or images are included in this manuscript. Survival analysis revealed no significant differences when using arterial (p = 0.161) or venous (p = 0.668) phase features alone. However, combining arterial and venous phase features significantly improved survival prediction (p = 0.007). Key predictive features included "Shape: Sphericity" and "Gray Level Size-Zone Non-Uniformity (GLSZM)". Combining arterial and venous phase radiomic features enhances survival prediction in PPPD-treated PaHCa patients, highlighting the potential of multi-phase CT radiomics for personalized treatment strategies. Radiomics-based survival prediction of PaHCa prior to patients undergoing PPPD may guide clinical decision-making and improve personalized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.